ClinicalTrials.gg
RecruitingNCT05398367Updated Mar 28, 2025

Galactagogue Use in Lactating Women With Low Milk Supply

An interventional study of Galactagogue Supplement for Treatment of Low Milk Supply in Breast Milk Expression, sponsored by Winthrop University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by Winthrop University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Breast Milk Expression with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Breast Milk Expression · United States.

Planned enrollment
7th of 22
120 · median 52
Started
2024
with 1 other
No phase
21 of 32
4 open now
Registered
22nd of 32
by date

Among the 32 studies in Breast Milk Expression with a site in United States, this one is the 7th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2024, is one of 21 with no phase, and was the 22nd registered.

Breast Milk Expression

88 studies on the registry are indexed under Breast Milk Expression; 19 are open to participants now.

Browse Breast Milk Expression studies →

Open to participants now

6 of the 32 studies in Breast Milk Expression with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Breast Milk Expression studies recruiting now, 6 (46%) set no upper age limit and 7 (54%) stop at 75 or younger; 3 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Milk Expression with a site in United States, or all of them as a file.
02

Study summary

This study aims to determine whether a 20-day supplement with either Oat Mama Lactation Supplement, moringa, or shatavari has any impact on milk production through an increase in serum prolactin levels when compared to the placebo group. This data will be used to determine if clinical recommendations can be made for the use of the studied supplements in increasing milk supply.

Read the detailed description

This study will be a double-blind randomized control trial where eligible participants will be randomized into one of four treatment groups: Oat Mama Lactation Supplement (O), moringa supplement (M), shatavari supplement (S), or control (C). All participants will receive a supplement or placebo for consumption throughout the 20-day trial period, and all participants will receive support from a lactation consultant once per week to receive appropriate guidance for increasing milk supply. 24-hour milk output will be recorded on day 1, 10, and 20 using either pre- and post-feeding weights, 24-hour pump output, or a combination of both. Additionally, blood samples will be taken on day 1, 10, and 20 and serum will be isolated for later analysis of serum prolactin levels.

03

Conditions studied

  • Breast Milk Expression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Participants in the study must:

  • Be struggling with diagnosed or perceived low milk supply
  • Be willing to consume a randomly assigned galactagogue or placebo supplement
  • Be willing to provide a blood sample at each lactation consult (day 1, 10, 20)
  • Be willing to provide 24-hour expressed milk volume either using pre- and post-feed weights, total pump output, or a combination of both on day 1, 10, and 20

Exclusion Criteria: Participants will be excluded if:

  • They have a history of breast reduction
  • They have a history of utilizing in vitro fertilization
  • They are not a biological female with mammary glands present for producing milk
  • They have consumed galactagogues with the intention of increasing their milk supply during the current lactation cycle
  • They are under age 18 or above age 39
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Oat Mama Lactation Supplement

    Participants will receive a 20 day supply of oat mama lactation supplement for consumption per the manufacturer instructions

    Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply

  • Experimental
    Moringa Supplement

    Participants will receive a 20 day supply of moringa supplement for consumption per the manufacturer instructions

    Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply

  • Experimental
    Shatavari Supplement

    Participants will receive a 20 day supply of shatavari supplement for consumption per the manufacturer instructions

    Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply

  • Placebo comparator
    Placebo

    Participants will receive a 20 day supply of placebo pills containing a mixture of flour and brown sugar. Participants will consume 2 placebo pills once per day for 20 days.

    Dietary Supplement: Galactagogue Supplement for Treatment of Low Milk Supply

Interventions

  • Dietary supplementGalactagogue Supplement for Treatment of Low Milk Supply

    Participants will consume a commercially available dietary supplement on the market for augmentation of breast milk production in lactating women with low milk supply

06

What researchers measure

Primary outcomes

  1. Change in Breast Milk Supply

    Change in breast milk supply will be evaluated using 24-hour breast milk expression volume

    Time frame: Intervention will last 20 days and 24-hour breast milk expression volume will be measured on day 1, 10, and 20 and used to calculate change in 24-hour breast milk expression volume over the trial period

  2. Change in Serum Prolactin

    Change in serum prolactin levels will be evaluated by taking blood samples on day 1, 10, and 20 and measuring serum prolactin using a human serum prolactin ELISA kit

    Time frame: Intervention will last 20 days and blood samples will be taken on day 1, 10, am 20 and change in serum prolactin will be measured using a human serum prolactin ELISA kit

07

Study locations

1 of 1 sites recruiting
  • Winthrop University
    Rock Hill, South Carolina 29733, United States
    Recruiting
    • Hope K Lima, PhD · Contactlimah@winthrop.edu · 803-323-4540
    • Hope K Lima, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — There will be no sharing of individual participant data to researchers outside of the experimental team.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2025, 14 months after the start.

Of 32 non-industry interventional studies with no phase under Breast Milk Expression, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 14 months is close to that.

Counting every sponsor, half of 39 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
Jun 1, 2022
StartActual
Mar 5, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2026
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05398367
Lead sponsor
Winthrop University
Responsible party
Hope Lima (Assistant Professor and Graduate Director, Winthrop University) — Principal investigator
First posted
Jun 1, 2022
Start date
Mar 5, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Mar 28, 2025

Study contacts

Hope K Lima, PhD
Contact
limah@winthrop.edu
803-323-4540
Hope K Lima, PhD
principal investigator · Winthrop University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion